Drug Trial Radar · NCT04590586
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
Last checked: Nov 20, 2026Latest source record: Jun 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
515
Actual
Start
Nov 24, 2020
Primary completion
Aug 3, 2021
Study completion Aug 3, 2021
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.
Conditions
- COVID-19
Interventions
Standard of careDrug
Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
ApremilastDrug
Apremilast administered orally as a tablet.
Apremilast placeboDrug
Matching apremilast placebo administered orally as a tablet.
LanadelumabDrug
Lanadelumab administered as an intravenous (IV) infusion.
Lanadelumab placeboDrug
Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
ZilucoplanDrug
Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Zilucoplan placeboDrug
Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
- Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
- Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Locations
59 sites in 8 countries. Site status is shown where the registry gives one.
Pinnacle Research Group LLC
Anniston, Alabama
Good Samaritan Hospital
Bakersfield, California
Sharp Chula Vista Medical Center
Chula Vista, California
El Centro Regional Medical Center
El Centro, California
University of California Irvine Medical Center
Orange, California
Riverside Community Hospital
Riverside, California
University of California Davis Health System
Sacramento, California
National Institute of Clinical Research
South El Monte, California
UF Health Shands Hospital
Gainesville, Florida
Memorial Hospital Jacksonville
Jacksonville, Florida
Grady Health System
Atlanta, Georgia
Great Lakes Clinical Trials
Chicago, Illinois
The University of Iowa
Iowa City, Iowa
Harper University Hospital
Detroit, Michigan
Sinai Grace Hospital
Detroit, Michigan
Detroit Receiving Hospital
Royal Oak, Michigan
University of Tennessee Health Sciences Center
Memphis, Tennessee
Medical City Ft. Worth
Fort Worth, Texas
University of Texas Health Science Center at Houston
Houston, Texas
Texoma Medical Center
Sherman, Texas
MultiCare Health System Institute for Research and Innovation
Tacoma, Washington
Hospital General de Agudos Dr. J. M. Ramos Mejia
Ciudad Autonoma Buenos Aires, Argentina
Hospital General de Agudos Dr. Ignacio Pirovano
Ciudad Autonoma Buenos Aires, Argentina
Clinica Adventista Belgrano
Ciudad Autonoma Buenos Aires, Argentina
Hospital Italiano de Rosario
Rosario, Argentina
Hospital San Juan de Dios
Ramos Mejía, Buenos Aires, Argentina
Chronos Pesquisa Clinica
Brasília, Federal District, Brazil
HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás
Goiânia, Goiás, Brazil
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
Botucatu, São Paulo, Brazil
Praxis Pesquisa Médica
Santo André, São Paulo, Brazil
Hospital Base Osorno
Osorno, Chile
Hospital General de Tijuana
Tijuana, Baja California Norte, Mexico
Hospital Civil de Guadalajara Dr. Juan I. Menchaca
Guadalajara, Jalisco, Mexico
Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez
Monterrey, Nuevo León, Mexico
Hospital Civil de Culiacan
Culiacán, Sinaloa, Mexico
TSBIH "Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich
Krasnoyarsk, Russia
SBIH of Moscow "Infectious Clinical Hospital # 1 of Department of Healthcare of Moscow"
Moscow, Russia
SPb SBIH "Alexandrovskaya City Hospital"
Saint Petersburg, Russia
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.